Response to Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL+ human leukemia"

Sci Transl Med. 2019 Jul 17;11(501):eaav0819. doi: 10.1126/scitranslmed.aav0819.

Abstract

LB100 sensitizes resistant chronic phase CML stem and progenitor cells to TKIs and spares healthy bone marrow cells.

Publication types

  • Comment

MeSH terms

  • Drug Resistance, Neoplasm / drug effects
  • Fusion Proteins, bcr-abl
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive*
  • Neoplastic Stem Cells / drug effects
  • Protein Kinase Inhibitors

Substances

  • Protein Kinase Inhibitors
  • Fusion Proteins, bcr-abl